Analysis of hematological indexes of COVID‐19 patients from fever clinics in Suzhou, China

作者：Jindan Kong, Ting Wang, Di Zou, Bingyu Shi, Xiaoming Yu, Chaofa Huang, Yan Yang, Haiwei Sun, Dejing Yuan, Depei Wu, Jianhong Fu · 发表于：International Journal of Laboratory Hematology · 年份：2020 · DOI：10.1111/ijlh.13290 · 被引用次数：13 · 研究领域：COVID-19 Clinical Research Studies、Sepsis Diagnosis and Treatment、Long-Term Effects of COVID-19

Dear Editors, The 2019 novel coronavirus, formally denominated as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused the pandemic of coronavirus disease 2019 (COVID-19). Early identification, diagnosis, quarantine, and centralized treatment are key factors in the Chinese experience of epidemic prevention and control. Fever clinics have been used for early identification of suspected COVID-19 patients in China, which proved to be an effective paradigm in several prior public health incidents, such as SARS in 2003. Patients with fever, respiratory symptoms, or related epidemiological history were guided to the fever clinics. Studies have reported that complete blood count (CBC) in COVID-19 patients and most of the leukocyte changes were not specific. A decrease in absolute lymphocyte count was frequently observed,1 and an elevation in D-dimer level was more common in severe COVID-19 cases.2 The present study aimed to explore practical biomarkers derived from a conventional hematological examination for COVID-19 management in fever clinics. According to the Chinese guideline for diagnosis and treatment of novel coronavirusinfected pnemomia, COVID-19 patients from six hospital fever clinics in Suzhou, whose diagnosis was confirmed by reverse transcription-polymerase chain reaction (RT-PCR), were enrolled between January 10 and March 1, 2020. All of these COVID-19 patients were transferred to the Affiliated Infectious Disease Hospital of Soochow University. S...